Duration of filgrastim prophylaxis for chemotherapy-induced neutropenia and its predictors / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 69-72, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-286753
ABSTRACT
<p><b>OBJECTIVE</b>To analyze the duration of preventive filgrastim administration as support for chemotherapy and its affecting factors.</p><p><b>METHODS</b>Single institutional data from a phase Ⅱ clinical trial and a phase Ⅲ clinical trial of pegylated filgrastim were combined. In the two randomized cross-over trials, patients with previously untreated cancer received two cycles of chemotherapy of the same regimen. In the study group, the patients received a single subcutaneous injection of 100 μg/kg pegylated filgrastim, and in the control group, they received daily subcutaneous injections of 5 μg/kg filgrastim.</p><p><b>RESULTS</b>In 53 chemotherapy cycles, the median duration of filgrastim administration was (9.57±2.10)d. 83.0% (44/53) of them received filgrastim for 7-11 days. Patients with baseline absolute neutrophil count of <4×10(9)/L or body mass index less than 22 received a longer filgrastim prophylaxis(P<0.05). RESULTS of multivariate analysis showed that the baseline absolute neutrophil count is associated with the time of filgrastim administration(P=0.019). The most common adverse event of rhG-CSF was skeletal pain, generally mild and no treatment-related death occurred.</p><p><b>CONCLUSIONS</b>The median duration of filgrastim support for chemotherapy was 10 days. Patients with lower baseline neutrophil count require a longer filgrastim prophylaxis.</p><p><b>TRIAL REGISTRATION</b> ClinicalTrials.gov identifier, NCT01285219.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Time Factors
/
Multivariate Analysis
/
Cross-Over Studies
/
Therapeutic Uses
/
Drug Therapy
/
Induction Chemotherapy
/
Filgrastim
/
Hematologic Agents
/
Injections, Subcutaneous
/
Neoplasms
Type of study:
Controlled clinical trial
/
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS